Diamyd Medical: Diamyd's Phase III studies continue to follow plan.

In her comments in quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical (Diamyd), describes the progress in the decisive Phase III studies with the company's lead drug candidate Diamyd, and comments on the company's strategies and efforts to build a Nordic speciality pharmaceutical company. She said the company has only one year to go before they have the results from European Phase III study. The company will primarily focus on completing the Phase III studies and prepare for market launch of Diamyd. During the report period Diamyd could announce that the US FDA approved the experimental use of Diamyd in children as young as 3 years of age in the TrialNet GAD study. …